Encellin is pioneering advancements in therapeutic technologies through its Encapsulated Cell Replacement Therapy (EnCRT), which is designed to address endocrine disorders. This innovative approach allows for the encapsulation of cells within a proprietary nano-porous material, enabling these cells to function as "smart factories" that release therapeutics in response to the body's needs. The EnCRT is constructed to be minimally invasive, supporting cell viability and function while avoiding foreign body responses, which traditionally complicate cell transplantation. This technology aims to eliminate the necessity for conventional immunosuppression, thereby broadening the potential for various therapeutic applications.

The company's initial focus is on treating type 1 diabetes, particularly addressing hypoglycemia, which represents a significant unmet clinical need. Encellin's platform leverages well-established biocompatible materials and aims to utilize known functional cell therapies, such as islet cells, to facilitate early clinical entry. As the EnCRT platform demonstrates clinical validation, Encellin plans to expand its applications to more complex biological systems, including stem cells, gene therapy, and enzyme replacement therapies, thereby enhancing the scope of cell-based treatments for chronic diseases.

United States

Encellin is a biotechnology company specializing in cell encapsulation technology for cell-based therapeutics. The company's initial pipeline focuses on endocrine disorders with a clear mechanism of action, particularly focusing on Hypoglycemia. Encellin was founded based on the technology developed in the lab of Dr. Tejal Desai at the University of California in San Francisco.

Encellin

Company Details